



Published in final edited form as:

*J Psychiatr Res.* 2021 July ; 139: 99–105. doi:10.1016/j.jpsychires.2021.05.017.

## Dynamic Associations Between Anxiety, Depression, and Tobacco Use in Older Adults: Results From The Irish Longitudinal Study on Ageing

Derek C. Monroe<sup>1,2</sup>, Cillian P. McDowell<sup>3,4,5</sup>, Rose Anne Kenny<sup>3,4,6</sup>, Matthew P. Herring<sup>3,5,7</sup>

<sup>1</sup>Department of Kinesiology, University of North Carolina at Greensboro, NC, USA

<sup>2</sup>Department of Neurology, University of California-Irvine, Irvine, CA, USA

<sup>3</sup>The Irish Longitudinal Study on Ageing, Trinity College Dublin, Ireland

<sup>4</sup>School of Medicine, Trinity College Dublin, Ireland

<sup>5</sup>Physical Activity for Health Research Cluster, Health Research Institute, University of Limerick, Limerick, Ireland

<sup>6</sup>Mercer's Institute for Successful Ageing, St James's Hospital, Dublin, Ireland

<sup>7</sup>Department of Physical Education and Sport Sciences, University of Limerick, Limerick, Ireland

### Abstract

Evidence supports moderate-to-large reductions in anxiety, depression, and perceived stress after smoking cessation; however, much of the available evidence has focused on young adults. Therefore, this study quantified associations between smoking and smoking cessation on prevalent and incident generalised anxiety disorder (GAD) and major depression (MDD) in a nationally representative sample of Irish older adults. Participants (n=6,201) were community dwelling adults aged 50 years resident in Ireland. Smoking status and self-reported doctor diagnosis of anxiety or depression prior to baseline were assessed at baseline (i.e., Wave 2). At baseline and 2-, 4-, and 6-year follow-up (i.e., Waves 3–5), GAD and MDD were assessed by the Composite International Diagnostic Interview Short-Form. Logistic regression quantified cross-sectional and prospective associations (odds ratios (ORs) and 95% confidence intervals (95% CIs)) between smoking status and mental health. Prevalence and incidence of GAD was 9.1% (n=566) and 2.8% (n=148), respectively. Prevalence and incidence of depression was 11.1% (n=686) and 6.4% (n=342), respectively. Following full adjustment, current smokers had higher odds of prevalent

---

Corresponding Author Derek C. Monroe, PhD, Department of Kinesiology, 237 Coleman Building, 1408 Walker Avenue, University of North Carolina at Greensboro, Greensboro, NC 27402, Telephone: 336-334-5347, dcmunroe@uncg.edu.

#### Author Contributions

DCM, CPM, and MPH conceptualized this secondary analysis; CPM and MPH performed data curation and formal analyses; DCM contributed to the writing the original draft; all authors reviewed and edited the final draft.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declarations of interest: None.

Conflict of interest statement  
None declared.

GAD (OR=1.729, 1.332–2.449;  $p<0.001$ ) and MDD (OR=1.967, 1.548–2.499;  $p<0.001$ ) than non-smokers. Former smokers had higher odds of prevalent GAD than non-smokers (OR=1.276, 1.008–1.616;  $p<0.001$ ). Current smokers did not have higher odds of incident MDD (OR=1.399, 0.984–1.990;  $p=0.065$ ) or GAD than non-smokers (1.039, 0.624–1.730;  $p=0.881$ ). Findings may have important implications for interventions designed to curb tobacco abuse, which tend to be less successful among those with anxiety and depression.

## Keywords

Smoking; Smoking Cessation; Generalised Anxiety Disorder; Major Depression; Older Adults

---

## Introduction

Tobacco use is the leading cause of preventable death worldwide (WHO, 2017) and a substantial economic burden through healthcare costs and lost productivity (USDHHS, 2014; Xu, 2014). Though tobacco use was initially promoted as a method for improving affect and coping with daily emotional stressors (Ikard, 1969), substantial evidence supports the paradoxical impact of chronic smoking on mental health (Baker, 2004). These effects have been associated with nicotine, the primary dependence-forming chemical compound in tobacco reinforces smoking behaviour (Di Chiara, 2000) and, with chronic administration, can have catastrophic consequences for nervous system function (Dani, 2011; Middlekauff, 2014). The pharmacological actions of nicotine map onto Clark and Watson's (1991) tripartite model of anxiety and depression to explain the associations between emotional psychopathologies and tobacco dependence. As an extension of this model, Leventhal and Zvolensky (2015) propose a transdiagnostic vulnerability framework around the central tenet that emotional vulnerabilities (i.e., anxiety sensitivity, distress tolerance, and anhedonia), which can be traced to dysfunction in the same midbrain circuits that are disrupted by nicotine, contribute to and are exacerbated by smoking behaviour. Analysing longitudinal data through the lens of this framework may help to tease out these complex associations and inform interventional strategies.

Epidemiological evidence collected in young adults supports this approach, and data from nearly 200 longitudinal studies have collectively informed novel and tailored approaches to promote successful cessation in young adult smokers with mental health disorders (Fluharty et al., 2017; Stockings, Metse, Taylor, 2021; Taylor, 2014). However, considering the dose-dependent effects of chronic nicotine administration, these interventions may not be as efficacious for older adults, many of whom started smoking as young adults and thus have been smoking for years or decades longer than young adult smokers (Cataldo, 2019). Few interventions have been designed with a gerontological focus (Doolan, 2008) to address the lower intention to, and different reasons for, quitting that are commonly exhibited by older smokers (Jordan et al., 2016; Kerr, 2006; Lugo, 2013). Thus, characterizing the cross-sectional and longitudinal relationships between mental health and smoking behaviours among older adults is a necessary first step to facilitating smoking cessation in this population.

Anxiety and depression are the most common psychiatric diagnoses in older adults (Beaudreau & O'Hara, 2008), they are more prevalent in older adult smokers than non-smokers (An & Xiang, 2015; Bonnet et al., 2005) and can have profound effects on physical health (Lever-van Milligen et al., 2016; Penninx et al., 2000). Little is known about the risks of smoking on future mental health outcomes because of a lack of longitudinal studies. In two studies of older US adults, nicotine dependence was associated with a greater risk of developing anxiety but not future major depression (Chou, 2011; Sachs-Ericsson, 2011). However, both studies represent relatively small proportions of the ageing population, a bias which left uncorrected limits the generalizability of their findings to understand the effects of smoking on anxiety in depression in larger, non-US populations of older adult smokers. Lacking prospective data also contributes to a lack of knowledge about the effects of cessation on mental health outcomes in this population.

What we do know about cessation in older adults comes exclusively from cross-sectional comparisons of current and former smokers without prospective comparisons to help discern whether smoking likely contributed to psychiatric symptoms or vis versa. For example, current and past heavy smokers were 40 and 60% more likely to be clinically depressed than never or past light smokers, respectively, yet the reduction in risk between former and current smokers was statistically significant (Almeida & Pfaff, 2005; Lam, 2004). Similar reductions in relative risk for anxiety (24%) and depression (28%) were observed more recently in a small sample of older Chinese-American men (Li et al., 2019). There are also a handful of studies in which these the benefits of cessation for former smokers are not as large or statistically significant (e.g., Bazargan et al., 2020; Jing et al., 2020), though the lack of null-findings is probably due in part to a file-drawer effect. Ultimately, the cross-sectional nature of these studies means that the extent to which smoking cessation is prospectively associated with rates of anxiety and depression in older adults remains unclear.

A preliminary report from The Irish Longitudinal Study on Ageing (TILDA), a large ongoing cohort study that assesses the social, economic, and health circumstances of community dwelling adults aged 50 years resident in Ireland (Barrett et al., 2011), revealed that anxiety is more common than depression in Irish older adults, with 10% and 13% of participants reporting clinically significant depressive and anxiety symptoms, respectively (Barrett, 2011). Ancillary analyses showed relationships between tobacco use and ageing perceptions (Villiers-Tuthill, 2016) and cross-sectional associations between smoking status, smoking-related disease burden, and “mental health difficulties” among Wave 1 TILDA participants (Burns et al., 2017). However, cross-sectional and prospective associations between smoking status and individual mental health conditions were not investigated. Thus, to address the limitations of existing literature, we used data from TILDA Waves 2–5 to quantify associations of smoking and smoking cessation with prevalent and incident generalised anxiety disorder (GAD) and depression (MDD) in a representative sample of Irish older adults.

## Methods

This study used STROBE recommendations to guide reporting (von Elm et al., 2008).

## Ethics

The Irish Longitudinal Study on Ageing (TILDA) was approved by the Faculty of Health Sciences Research Ethics Committee at Trinity College Dublin. All experimental procedures adhered to the Declaration of Helsinki. All participants gave written informed consent and assessments were carried out by trained research nurses.

## Study design

This is a cross-sectional and prospective study examining the association of smoking with GAD and MDD. This study is embedded within TILDA, a large population-based study of a nationally representative sample of over 8000 community dwelling older adults aged 50 years. Details of the methodology employed by TILDA are fully described elsewhere (Kearney et al., 2011; Kenny et al., 2010; Whelan and Savva, 2013). Data were analysed from Wave 2 (i.e., baseline) through Wave 5 of TILDA. Participants were considered for cross-sectional analyses if they were aged 50 years at Wave 1, reported that they had never been told by a doctor that they had dementia, had data on smoking, GAD, and depression at baseline, and had follow-up data on either GAD or depression (n=6274). As physical activity was planned as a key covariate, physical activity data were processed consistent with standard guidelines/procedures for the International Physical Activity Questionnaire, such that unreasonable values of 16 hours of moderate and/or vigorous physical activity were excluded (Craig et al., 2003). Thus, participants with missing covariate data or who reported 16 hours of physical activity per day were then excluded (n=73; 1.2% of total), leaving a final sample of 6201 for cross-sectional analyses. Participants were included in prospective analyses if they were also free from GAD or MDD at baseline and reported having never been told by a doctor that they had anxiety or depression (n=5309).

## Smoking

Participants were asked whether they had ever smoked 'cigarettes, cigars, cigarillos or a pipe daily for a period of at least one year.' Those who answered 'No' were categorised as 'Never' smokers. Those who answered 'Yes' were asked if they smoked at the present time, including the past three months. If they answered 'No' they were categorised as 'Former' smokers, and if they answered 'Yes' they were categorised as 'Current' smokers.

## GAD and MDD

The Composite International Diagnostic Interview Short-Form (CIDI-SF) was used by trained interviewers at Wave 2 through Wave 5 to determine fulfilment of criteria for GAD and a major depressive episode in the last twelve months (Kessler et al., 1998). Participants were categorised as having GAD if they reported: 1) a period of worry lasting at least five months, 2) severe worry, 3) difficult to control worry, and 4) three of seven additional physiological symptoms. Compared to the full CIDI in the US National Comorbidity Survey, the CIDI-SF has demonstrated sensitivity of 96.6%, specificity of 99.8%, positive predictive value of 96.8%, negative predictive value of 99.8%, and total classification accuracy of 99.6% for GAD. Participants were categorised as having had MDD if they reported: 1) feeling depressed or a loss of interest in most activities at least almost every day for at least most of the day in the past 12 months as well as three or more additional depression

symptoms out of six assessed, or 2) loss of interest in most activities almost every day at least most of the day for two weeks or more in a row in the past 12 months as well as three or more additional depression symptoms out of six assessed. Compared to the full CIDI in the US National Comorbidity Survey, the CIDI-SF has demonstrated sensitivity of 89.6%, specificity of 93.9%, positive predictive value of 75.7%, negative predictive value of 86.9%, and total classification accuracy of 93.2% (Kessler et al., 1998).

Participants were also asked if they had ever been told by a doctor that they had anxiety or depression at, or prior to, Wave 2. Participants were classified as having prevalent anxiety or depression if they answered yes or if they screened positive for GAD or an MDD in the Wave 2 CIDI-SF assessment. These participants were excluded from prospective analyses. Incidence of anxiety or depression was defined as screening positive for GAD or MDD in any of the Waves 3, 4, or 5 CIDI-SF assessments.

### Covariates

Covariates were selected based on logical, theoretical, and/or prior empirical associations with smoking, depression, and/or anxiety and were measured at baseline. They included socio-demographic information, including age (years), sex (male, female), education level (primary/none, secondary level, third level or higher), and marital status (married/living together as if married, not married, separated/divorced, widowed). Physical activity was measured using the short-form International Physical Activity Questionnaire (Craig et al., 2003). Participants were classified according to meeting WHO PA guidelines (i.e., 150 minutes weekly of MVPA or 75 minutes weekly of vigorous PA, or an equivalent combination; WHO, 2010). Chronic conditions included lung disease, asthma, arthritis, osteoporosis, cancer, Parkinson disease, stomach ulcer, varicose ulcer, liver disease, thyroid disease, or kidney disease. Cardiovascular conditions included hypertension, stroke, angina, heart attack, heart murmur, or abnormal heart rhythm. Participants were classified as having none, one or two, or 3 chronic conditions, and none, one or two, or 3 cardiovascular conditions. Number of physical limitations was determined by asking about, and subsequently summing the number of, difficulties with walking, running, sitting, sit-to-stand, stair climbing, reaching overhead, stooping, kneeling, crouching, lifting heavy weights, pushing or pulling large objects and picking small coins from a table.

### Statistical analyses

Data were analysed in Stata version 14.2 (StataCorp for Windows). Participant characteristics were described by means and standard deviations for continuous variables and frequencies for categorical variables. Binary logistic regression quantified crude and adjusted associations (i.e., odds ratios (ORs) and associated 95% confidence intervals (95% CIs)) between smoking and prevalent and incident GAD and depression. Data were weighted with an inverse probability weight using the *svy* command in STATA to be representative of the population of adults aged 50 in Ireland.

## Results

### Participant characteristics

Characteristics of the analytic sample are presented in Table 1. Briefly, participants (n=6201) were predominantly female (55%) and aged 64 years. Overall, 45% (n=2794) never smoked, 41% (n=2483) were former smokers, and 15% (n=924) were current smokers. Prevalence and incidence of GAD was 9.1% (n=566) and 2.8% (n=148), respectively. Prevalence and incidence of depression was 11.1% (n=686) and 6.4% (n=342), respectively.

### GAD

Table 2 presents ORs for the associations between smoking and prevalent and incident GAD. Briefly, fully adjusted cross-sectional and prospective results are as follows. Compared to non-smoking, prior smoking (OR=1.276, 95%CI=1.008–1.616;  $p=0.043$ ) and current smoking (1.729, 1.332–2.449;  $p<0.001$ ) were associated with prevalent GAD. Prior smoking (1.041, 0.672–1.614;  $p=0.856$ ) and current smoking (1.039, 0.624–1.730;  $p=0.881$ ) were not associated with developing GAD.

### MDD

Table 2 presents ORs for the associations between smoking and prevalent and incident MDD. Briefly, fully adjusted cross-sectional and prospective results are as follows. Compared to non-smoking, prior smoking (1.191, 0.958–1.482;  $p=0.116$ ) was not associated with prevalent depression, but current smoking was (1.967, 1.548–2.499;  $p<0.001$ ). Former (1.183, 0.889–1.573;  $p=0.248$ ) and current (1.399, 0.984–1.990;  $p=0.061$ ) smokers did not have higher odds developing depression than non-smokers, respectively.

## Discussion

Leventhal's and Zvolensky's (2015) integrative model proposes that the reward associated with smoking is enhanced by emotional vulnerabilities which ultimately potentiate smoking behaviour: anhedonia amplifies the pleasure-enhancing effects of smoking, anxiety sensitivity amplifies smoking's anxiolytic effects, and poor distress tolerance amplifies the distress terminating effects of smoking. Within the context of this model, we report three noteworthy associations between mental health outcomes and smoking status from cross-sectional and prospective observations of a representative sample of ageing Irish adults.

First, current smokers were nearly twice as likely to report prevalent MDD (i.e. past or current MDD) compared to non-smokers. These patterns support the conclusions of a recent systematic review and qualitative synthesis of 297 studies that chronic smoking perpetuates negative affect and anhedonia, which may collectively act to stymie attempts at cessation (Mathew, 2016). Since this association was purely cross-sectional, it is possible that this pattern emerges from MDD as a risk factor for initiation of smoking behaviour. On one hand, former smokers exhibited no greater odds of MDD than non-smokers, suggesting that this alternative explanation is less likely. On the other hand, it might be that MDD makes quitting more difficult, meaning that smokers with MDD were at lower odds of becoming former smokers. Also notable for the interpretation of this pattern is the lack of

a greater prospective risk for current smokers to develop MDD. Thus, it is possible that the neurobiological effects of nicotine administration that perpetuate anhedonia occur proximal to when smoking is initiated, do not change over the course of maintenance, and then abate relatively quickly if administration ceases (Leventhal et al., 2009).

Second, current smokers had 73% higher odds of prevalent GAD, a pattern consistent with a review of 47 population-based epidemiological studies (Moylan et al., 2012), and former smokers were 27% more likely to report prevalent GAD compared to non-smokers. This pattern is also consistent with a proposed role of anxiety as a risk factor for nicotine dependence: elevated negative affect during abstinence, appraisal of these symptoms as harmful (i.e., anxiety sensitivity), and expectancy that smoking will reduce negative affect underpin associations between smoking and prevalent GAD (Piper et al., 2011; Zvolensky et al., 2004; Tidey and Miller, 2015). This interpretation is supported by previous reports that adult smokers with GAD report more severe nicotine dependence (Piper et al., 2010) and higher negative affect, even before cessation, (Piper et al., 2011) compared to smokers without GAD. These associations may also represent the deleterious effects of chronic smoking behaviour on structure (Fritz, 2014; Zorlu, 2017) and function (Claus, 2020; Pariyadath, 2014) in emotional control brain networks, features which have also been reported to predict cessation success (Addicott, 2015; Froeliger, 2015; Li, 2017). The time-course of these changes in the human brain likely aggregate over time and are unlikely to abate immediately upon cessation (Karama, 2015; McClernon, 2015), thus explaining why former smokers exhibited an elevated risk of anxiety at initial assessment, but not at follow-up.

Third, we also observed that current smokers exhibited no practical increase in odds of incident GAD (3.9%), but moderately, albeit statistically non-significant, greater odds of incident MDD (39%) when compared to non-smokers. A moderate-to-large and statistically significant greater odds of developing MDD was also observed in current smokers relative to former smokers prior to statistical adjustment. Although speculative, this might mean that the effects of smoking on depression may not be due to the pharmacological effects of smoking per se, but also might be attributed to mediating or moderating intermediate variables, such as sex or physical activity, that have known prospective associations with MDD and were controlled for in this study. Greater variability (i.e., large confidence intervals) was also observed in prevalent and incident MDD and GAD among current smokers compared to former smokers. Although this may simply be a function of a smaller sample of current smokers, it is also possible that this variability is biologically meaningful and represents moderating genetic, biological, or cognitive factors (Kendler et al., 1993, Qiao et al., 2020).

As in all epidemiological cohort studies it is possible that any of these unmeasured variables might also explain the cross-sectional associations we observed. For example, there is evidence that high neuroticism or extraversion, as personality types that tend to be associated with high anxiety, may also increase the risk of smoking (Hu et al., 2000; McCrae, Costa, and Bosse, 1978;). However, a strength of the current study was the adjustment of the statistical models for demographic, medical, and behavioural covariates. This means that a third variable would need to be largely independent of these covariates in order to

meaningfully explain the observed patterns. Although personality was not controlled for, the relationships between personality, anxiety, and smoking may be different for male and female smokers (Spielberger & Jacobs, 1982), thus adjustment of the current models for sex would have greatly reduced the influence of personality on the observed patterns.

These findings may have implications for interventions designed to curb tobacco abuse, which tend to be less successful among those with anxiety and depression (Haller, 2014; Watson, 2012), thus explaining the disproportionate rates of tobacco-related mortality in these populations (Prochaska et al., 2017). For example, in a recent sample of 1,162 English adults who reported currently smoking or having stopped within the past 12 months, despite smokers who reported depression/anxiety recalling a greater offer of support to stop smoking by their General Practitioner, this did not translate into use of a cessation aid or successful cessation (McGowan et al., 2018). One interpretation of the patterns reported herein is that, while anhedonia keeps ageing adults smoking (and abates after successful cessation), anxiety sensitivity lingers longer after attempted abstinence and may promote relapse among older smokers. This conceptualization is supported by the broad use of anti-depressants (e.g., bupropion) that attenuate cravings via altered neurotransmission in midbrain emotional control circuits (Culbertson et al., 2011; Simon et al., 2004) and tend to work better when combined with behavioural therapies (Secades-Villa, 2017; Das, 2017). We speculate that it may be useful to target anxiety sensitivity, as a trait that is exacerbated by smoking but not wholly targeted by these drugs, through behavioural therapies with demonstrated anxiolytic properties.

Exercise is one such therapy with demonstrated anxiolytic effects that has been demonstrated as an effective adjuvant for traditional cessation therapies. The associations reported here were corrected for individual differences in physical activity at baseline, meaning that the cross-sectional associations with GAD and MDD cannot be attributed to variability in physical activity. However, physical activity is also dynamic and thus it possible that prospective effects of smoking (or lack thereof) might be due partly to changes in physical activity. Higher physical activity levels are associated with lower incident anxiety, depression, and GAD (McDowell et al., 2018a, 2018b, 2019), less smoking behaviour (Taylor et al., 2005), and a greater likelihood of a successful quit attempt (Marcus, 1999; Zvolensky, 2018). A single bout of even low-to-moderate intensity exercise may curb cravings and improve mood and affect (Roberts, 2012) by acting on emotional and cognitive control brain circuits (Monroe, 2020; Van Rensburg, 2009). Therefore, a physical activity intervention initiated prior to cessation may be effective as a prophylactic to curb both anhedonia and anxiety sensitivity (Ussher, 2014; Rollo, 2019). A recent well-designed randomized control trial suggested that vigorous-intensity exercise may improve the odds of successful quitting in young adults with high anxiety sensitivity (Smits, 2016). However, even in smokers that do not ultimately quit, we speculate exercise may modify act through different mechanisms to reduce the risk of GAD and MDD.

## Limitations

Firstly, the smoking measure was somewhat crude, and this study would benefit from a more finite measure of nicotine exposure or dependence. Secondly, as with all observational



studies, there is the potential for residual confounding. Nonetheless, we controlled for key factors in analyses, including other lifestyle behaviours, such as physical activity, physical health, and prior mental health problems in prospective analyses. Finally, these findings are only representative of those aged 50 years in Ireland; it is plausible that age-related, geographic, and cultural differences exist.

## Conclusion

Smoking is associated with increased odds of prevalent GAD and MDD. Even smokers who have quit exhibited greater odds of prevalent GAD relative to older adults who have never smoked. These findings may have important implications for interventions designed to curb tobacco abuse among older adults, which tend to be less effective for those with anxiety and depression.

## References

- Addicott MA, Sweitzer MM, Froeliger B, Rose JE, & McClernon FJ (2015). Increased functional connectivity in an insula-based network is associated with improved smoking cessation outcomes. *Neuropsychopharmacol*, 40(11), 2648–2656. 10.1038/npp.2015.114
- Almeida OP, & Pfaff JJ (2005). Depression and smoking amongst older general practice patients. *J. Affect. Disord*, 86(2–3), 317–321. 10.1016/j.jad.2005.02.014 [PubMed: 15935254]
- An R, & Xiang X (2015). Smoking, heavy drinking, and depression among US middle-aged and older adults. *Prev. Med*, 81, 295–302. 10.1016/j.ypmed.2015.09.026 [PubMed: 26436684]
- Baker TB, Brandon TH, & Chassin L (2004). Motivational influences on cigarette smoking. *Annu. Rev. Psychol*, 55, 463–491. 10.1146/annurev.psych.55.090902.142054 [PubMed: 14744223]
- Barrett A, Burke H, Cronin H, Hickey A, Kamiya Y, Kenny RA, ... & Mosca I (2011). Fifty plus in Ireland 2011: first results from the Irish Longitudinal Study on Ageing (TILDA)
- Bazargan M, Cobb S, Castro Sandoval J, & Assari S (2020). Smoking status and well-being of underserved African American Older Adults. *Behav. Sci*, 10(4), 78. 10.3390/bs10040078
- Beaudreau SA, & O'Hara R (2008). Late-life anxiety and cognitive impairment: a review. *Am. J. Geriatr. Psychiatry*, 16(10), 790–803. 10.1097/JGP.0b013e31817945c3 [PubMed: 18827225]
- Bonnet F, Irving K, Terra JL, Nony P, Berthezène F, & Moulin P (2005). Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. *Atherosclerosis*, 178(2), 339–344. 10.1016/j.atherosclerosis.2004.08.035 [PubMed: 15694943]
- Burns A, Strawbridge JD, Clancy L, & Doyle F (2017). Exploring smoking, mental health and smoking-related disease in a nationally representative sample of older adults in Ireland—A retrospective secondary analysis. *J. Psychosom. Res*, 98, 78–86. 10.1016/j.jpsychores.2017.05.005 [PubMed: 28554376]
- Cataldo JK (2019). Double Whammy for Older Smokers: Marginalized by Tobacco Control and Valued by the Tobacco Industry. *West. J. Nurs. Res*, 41(8), 1137–1151. 10.1177/0193945919845376 [PubMed: 31035868]
- Chou KL, Mackenzie CS, Liang K, & Sareen J (2011). Three-year incidence and predictors of first-onset of DSM-IV mood, anxiety, and substance use disorders in older adults: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *J. Clinl Psychiatry* 10.4088/JCP.09m05618gry
- Clark LA, & Watson D (1991). Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. *J. Abnorm. Psych*, 100(3), 316. 10.1037//0021-843x.100.3.316
- Claus ED, & Weywadt CR (2020). Resting-State Connectivity in Former, Current, and Never Smokers. *Nicotine Tob. Res*, 22(2), 180–187. 10.1093/ntr/nty266 [PubMed: 30590742]
- Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, ... & Oja P (2003). International physical activity questionnaire: 12-country reliability and validity. *Med. Sci. Sports Exerc*, 35(8), 1381–1395. 10.1249/01.MSS.0000078924.61453.FB [PubMed: 12900694]

- Culbertson CS, Bramen J, Cohen MS, London ED, Olmstead RE, Gan JJ, ... & Brody AL (2011). Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers. *Arch. Gen. Psychiatry*, 68(5), 505–515. 10.1001/archgenpsychiatry.2010.193 [PubMed: 21199957]
- Dani JA, Jenson D, Broussard JI, & De Biasi M (2011). Neurophysiology of nicotine addiction. *J. Addict. Res. Ther.*, (1). 10.4172/2155-6105.S1-001
- Das S, & Prochaska JJ (2017). Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders. *Expert Rev. Respir. Med.*, 11(10), 841–850. 10.1080/17476348.2017.1361823 [PubMed: 28756728]
- Di Chiara G (2000). Role of dopamine in the behavioural actions of nicotine related to addiction. *Eur. J. Pharmacol.*, 393(1–3), 295–314. 10.1016/S0014-2999(00)00122-9 [PubMed: 10771025]
- Doolan DM, & Froelicher ES (2008). Smoking cessation interventions and older adults. *Prog. Cardiovasc. Nurs.*, 23(3), 119–127. 10.1111/j.1751-7117.2008.00001.x [PubMed: 19039892]
- Fluharty M, Taylor AE, Grabski M, & Munafò MR (2016). The association of cigarette smoking with depression and anxiety: a systematic review. *Nicotine Tobacco Res.*, 19(1), 3–13. 10.1093/ntr/ntw140
- Fritz HC, Wittfeld K, Schmidt CO, Domin M, Grabe HJ, Hegenscheid K, ... & Lotze M (2014). Current smoking and reduced gray matter volume—a voxel-based morphometry study. *Neuropsychopharmacol.*, 39(11), 2594–2600. 10.1038/npp.2014.112
- Froeliger B, McConnell PA, Stankeviciute N, McClure EA, Kalivas PW, & Gray KM (2015). The effects of N-acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: a double-blind, placebo-controlled fMRI pilot study. *Drug Alcohol Depend.*, 156, 234–242. 10.1016/j.drugalcdep.2015.09.021 [PubMed: 26454838]
- Gallus S, Muttarak R, Franchi M, Pacifici R, Colombo P, Boffetta P, ... & La Vecchia C (2013). Why do smokers quit?. *Eur. J. Cancer Prev.*, 22(1), 96–101. 10.1097/CEJ.0b013e3283552da8 [PubMed: 22644233]
- Haller CS, Etter JF, & Courvoisier DS (2014). Trajectories in cigarette dependence as a function of anxiety: a multilevel analysis. *Drug Alcohol Depend.*, 139, 115–120. [PubMed: 24703608]
- He W, Goodkind D, & Kowal PR (2016). An aging world: 2015.
- Hu S, Brody CL, Fisher C, Gunzerath L, Nelson ML, Sabol SZ, ... & Hamer DH (2000). Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior. *Mol. Psychiatry*, 5(2), 181–188. 10.1038/sj.mp.4000690 [PubMed: 10822346]
- Ikard FF, Green DE, & Horn D (1969). A scale to differentiate between types of smoking as related to the management of affect. *Int. J. Addict.*, 4(4), 649–659. 10.3109/10826086909062040
- Jane-Llopis EVA, Jané-Llopis E, Matytsina I, Jané-Llopis E, & Matytsina I (2006). Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. *Drug Alcohol Rev.*, 25(6), 515–536. [PubMed: 17132571]
- Jordan H, Hidajat M, Payne N, Adams J, White M, & Ben-Shlomo Y (2017). What are older smokers' attitudes to quitting and how are they managed in primary care? An analysis of the cross-sectional English Smoking Toolkit Study. *BMJ open*, 7(11), e018150. 10.1136/bmjopen-2017-018150
- Jing Z, Li J, Wang Y, Yuan Y, Zhao D, Hao W, ... & Zhou C (2020). Association of smoking status and health-related quality of life: difference among young, middle-aged, and older adults in Shandong, China. *Qual. Life Res.*, 1–10. 10.1007/s11136-020-02645-9
- Karama S, Ducharme S, Corley J, Chouinard-Decorte F, Starr JM, Wardlaw JM, ... & Deary IJ (2015). Cigarette smoking and thinning of the brain's cortex. *Mol. Psychiatry*, 20(6), 778–785. 10.1038/mp.2014.187 [PubMed: 25666755]
- Kearney PM, Cronin H, O'Regan C, Kamiya Y, Whelan BJ, & Kenny RA (2011). Comparison of centre and home-based health assessments: early experience from the Irish Longitudinal Study on Ageing (TILDA). *Age Ageing*, 40(1), 85–90. 10.1093/ageing/afq124 [PubMed: 20870732]
- Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, & Kessler RC (1993). Smoking and major depression: a causal analysis. *Arch. Gen. Psychiatry*, 50(1), 36–43. 10.1001/archpsyc.1993.01820130038007 [PubMed: 8422220]
- Kenny RA, Whelan BJ, Cronin H, Kamiya Y, Kearney P, O'Regan C, & Ziegel M (2010). The design of the Irish longitudinal study on ageing

- Kerr S, Watson H, Tolson D, Lough M, & Brown M (2006). Smoking after the age of 65 years: a qualitative exploration of older current and former smokers' views on smoking, stopping smoking, and smoking cessation resources and services. *Health Soc. Care Community*, 14(6), 572–582. 10.1111/j.1365-2524.2006.00659.x [PubMed: 17059499]
- Kessler RC, Andrews G, Mroczek D, Ustun B, & Wittchen HU (1998). The World Health Organization composite international diagnostic interview short- form (CIDI- SF). *International J. Methods Psychiatric Res*, 7(4), 171–185. 10.1002/mpr.47
- Lam TH, Li ZB, Ho SY, Chan WM, Ho KS, Li MP, & Leung GM (2004). Smoking and depressive symptoms in Chinese elderly in Hong Kong. *Acta Psychiatrica Scandinavica*, 110(3), 195–200. 10.1111/j.1600-0447.2004.00342.x [PubMed: 15283739]
- Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, & Bor DH (2000). Smoking and mental illness: a population-based prevalence study. *Jama*, 284(20), 2606–2610. 10.1001/jama.284.20.2606 [PubMed: 11086367]
- Leventhal AM, Kahler CW, Ray LA, & Zimmerman M (2009). Refining the depression-nicotine dependence link: patterns of depressive symptoms in psychiatric outpatients with current, past, and no history of nicotine dependence. *Addict. Behav*, 34(3), 297–303. 10.1016/j.addbeh.2008.11.008 [PubMed: 19062199]
- Leventhal AM, & Zvolensky MJ (2015). Anxiety, depression, and cigarette smoking: A transdiagnostic vulnerability framework to understanding emotion–smoking comorbidity. *Psychol. Bull*, 141(1), 176. 10.1037/bul0000003 [PubMed: 25365764]
- Lever- van Milligen BA, Lamers F, Smit JH, & Penninx BW (2017). Six- year trajectory of objective physical function in persons with depressive and anxiety disorders. *Depression and anxiety*, 34(2), 188–197. 10.1002/da.22557 [PubMed: 27701790]
- Li CC, Matthews AK, Dong X, & Simon M (2019). The influence of smoking status on the health profiles of older Chinese American men. *J. Am. Geriatr. Soc*, 67(S3), S577–S583. 10.1111/jgs.15889 [PubMed: 31403203]
- Li X, Du L, Sahlem GL, Badran BW, Henderson S, & George MS (2017). Repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex reduces resting-state insula activity and modulates functional connectivity of the orbitofrontal cortex in cigarette smokers. *Drug Alcohol Depend*, 174, 98–105. 10.1016/j.drugalcdep.2017.02.002 [PubMed: 28319755]
- Lugo A, La Vecchia C, Boccia S, Murisic B, & Gallus S (2013). Patterns of smoking prevalence among the elderly in Europe. *Int. J. Environ. Res. Public Health*, 10(9), 4418–4431. 10.3390/ijerph10094418 [PubMed: 24048208]
- Marcus BH, Albrecht AE, King TK, Parisi AF, Pinto BM, Roberts M, ... & Abrams DB (1999). The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial. *Arch. Intern. Med*, 159(11), 1229–1234. 10.1001/archinte.159.11.1229 [PubMed: 10371231]
- Mathew AR, Hogarth L, Leventhal AM, Cook JW, & Hitsman B (2017). Cigarette smoking and depression comorbidity: systematic review and proposed theoretical model. *Addict*, 112(3), 401–412. 10.1111/add.13604
- McCleron FJ, Addicott MA, & Sweitzer MM (2015). Smoking abstinence and neurocognition: implications for cessation and relapse. In *The Neurobiology and Genetics of Nicotine and Tobacco* (pp. 193–227). Springer, Cham.
- McCrae RR, Costa PT Jr, & Bossé R (1978). Anxiety, extraversion and smoking. *British J. Social and Clin. Psychol*, 17(3), 269–273. 10.1111/j.2044-8260.1978.tb00277.x
- McDowell CP, Gordon BR, Andrews KL, MacDonncha C, & Herring MP (2019). Associations of physical activity with anxiety symptoms and status: results from the Irish Longitudinal Study on Ageing. *Epidemiol Psychiatr Sci*, 28(4), 436–445. 10.1017/S204579601800001X [PubMed: 29382402]
- McDowell CP, Dishman RK, Vancampfort D, Hallgren M, Stubbs B, MacDonncha C, & Herring MP (2018a). Physical activity and generalized anxiety disorder: results from The Irish Longitudinal Study on Ageing (TILDA). *International journal of epidemiology*, 47(5), 1443–1453. 10.1093/ije/dyy141 [PubMed: 29982489]

- McDowell CP, Dishman RK, Hallgren M, MacDonncha C, & Herring MP (2018b). Associations of physical activity and depression: Results from the Irish Longitudinal Study on Ageing. *Exp Gerontol*, 112, 68–75. 10.1016/j.exger.2018.09.004 [PubMed: 30217663]
- McGowan JA, Brown J, West R, Brose LS, & Shahab L (2018). Offer and use of smoking-cessation support by depression/anxiety status: a cross-sectional survey. *J Smok. Cessat*, 13(4), 207–215.
- Middlekauff HR, Park J, & Moheimani RS (2014). Adverse effects of cigarette and noncigarette smoke exposure on the autonomic nervous system: mechanisms and implications for cardiovascular risk. *J. Am. Coll. Cardiol* 64(16), 1740–1750. 10.1016/j.jacc.2014.06.1201 [PubMed: 25323263]
- Monroe DC, Patel NR, McCully KK, & Dishman RK (2020). The effects of exercise on mood and prefrontal brain responses to emotional scenes in smokers. *Physiol. Behav*, 213, 112721. 10.1016/j.physbeh.2019.112721 [PubMed: 31669233]
- Moylan S, Jacka FN, Pasco JA, & Berk M (2012). Cigarette smoking, nicotine dependence and anxiety disorders: a systematic review of population-based, epidemiological studies. *BMC Med*, 10(1), 123. 10.1186/1741-7015-10-123 [PubMed: 23083451]
- Pariyadath V, Stein EA, & Ross TJ (2014). Machine learning classification of resting state functional connectivity predicts smoking status. *Front. Hum. Neurosci*, 8, 425. 10.3389/fnhum.2014.00425 [PubMed: 24982629]
- Penninx BW, Deeg DJ, Van Eijk JTM, Beekman AT, & Guralnik JM (2000). Changes in depression and physical decline in older adults: a longitudinal perspective. *Journal of affective disorders*, 61(1–2), 1–12. 10.1016/S0165-0327(00)00152-X [PubMed: 11099735]
- Piper ME, Cook JW, Schlam TR, Jorenby DE, & Baker TB (2011). Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. *Addiction*, 106(2), 418–427. 10.1111/j.1360-0443.2010.03173.x [PubMed: 20973856]
- Piper ME, Smith SS, Schlam TR, Fleming MF, Bittrich AA, Brown JL, ... & Baker TB (2010). Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation. *J. Consult. Clin. Psychol*, 78(1), 13. 10.1037/a0018065 [PubMed: 20099946]
- Prochaska JJ, Das S, & Young-Wolff KC (2017). Smoking, mental illness, and public health. *Annu. Rev. Public Health*, 38, 165–185. 10.1146/annurev-publhealth-031816-044618 [PubMed: 27992725]
- Qiao H, Chen M, Li S, Li Y, Sun Y, & Wu Y (2020). Poor lung function accelerates cognitive decline in middle-aged and older adults: Evidence from the English Longitudinal Study of Ageing. *Arch. Gerontol. and Geriatr*, 104129. 10.1016/j.archger.2020.104129 [PubMed: 32502885]
- Roberts V, Maddison R, Simpson C, Bullen C, & Prapavessis H (2012). The acute effects of exercise on cigarette cravings, withdrawal symptoms, affect, and smoking behaviour: systematic review update and meta-analysis. *Psychopharmacol*, 222(1), 1–15. 10.1007/s00213-012-2731-z
- Rollo S, Sui W, & Prapavessis H (2019). Exercise as a Smoking Cessation Aid. In *Neurosci. Nicotine* (pp. 459–466). Academic Press. 10.1016/B978-0-12-813035-3.00055-1
- Sachs-Ericsson N, Collins N, Schmidt B, & Zvolensky M (2011). Older adults and smoking: Characteristics, nicotine dependence and prevalence of DSM-IV 12-month disorders. *Aging Mental Health*, 15(1), 132–141. 10.1080/13607863.2010.505230 [PubMed: 20924817]
- Secades-Villa R, González-Roz A, García-Pérez Á, & Becoña E (2017). Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: A systematic review and meta-analysis. *PloS One*, 12(12). 10.1371/journal.pone.0188849
- Simon JA, Duncan C, Carmody TP, & Hudes ES (2004). Bupropion for smoking cessation: a randomized trial. *Arch. Intern. Med*, 164(16), 1797–1803. 10.1001/archinte.164.16.1797 [PubMed: 15364675]
- Smits JA, Zvolensky MJ, Davis ML, Rosenfield D, Marcus BH, Church TS, ... & Brown RA (2016). The efficacy of vigorous-intensity exercise as an aid to smoking cessation in adults with high anxiety sensitivity: A randomized controlled trial. *Psychosom. Med*, 78(3), 354. 10.1097/PSY.0000000000000264 [PubMed: 26513517]

- Stockings E, Metse A, & Taylor G (2021). "It's the one thing they have left": smoking, smoking cessation and mental health. In *Supporting Tobacco Cessation (ERS Monograph)* (pp. 248–272). Sheffield, European Respiratory Society.
- Taylor AH, Katomeri M, & Ussher M (2005). Acute effects of self-paced walking on urges to smoke during temporary smoking abstinence. *Psychopharmacology*, 181(1), 1–7. 10.1007/s00213-005-2216-4 [PubMed: 15844010]
- Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, & Aveyard P (2014). Change in mental health after smoking cessation: systematic review and meta-analysis. *Bmj*, 348, g1151. 10.1136/bmj.g1151 [PubMed: 24524926]
- Tidey JW, & Miller ME (2015). Smoking cessation and reduction in people with chronic mental illness. *Bmj*, 351, h4065. 10.1136/bmj.h4065 [PubMed: 26391240]
- Ussher MH, Taylor AH, & Faulkner GE (2014). Exercise interventions for smoking cessation. *Cochrane Database Syst. Rev.* (8). 10.1002/14651858.CD002295.pub5
- US Department of Health and Human Services. (2014). *The health consequences of smoking—50 years of progress: a report of the Surgeon General*
- Van Rensburg KJ, Taylor A, Hodgson T, & Benattayallah A (2009). Acute exercise modulates cigarette cravings and brain activation in response to smoking-related images: an fMRI study. *Psychopharmacol*, 203(3), 589. 10.1007/s00213-008-1405-3
- Villiers-Tuthill A, Copley A, McGee H, & Morgan K (2016). The relationship of tobacco and alcohol use with ageing self-perceptions in older people in Ireland. *BMC Pub. Health*, 16(1), 627. [PubMed: 27448397]
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, & Strobe Initiative. (2008). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J. Clin. Epidemiol.* 61(4), 344–349. 10.1016/j.jclinepi.2007.11.008 [PubMed: 18313558]
- Watson NL, VanderVeen JW, Cohen LM, DeMarree KG, & Morrell HE (2012). Examining the interrelationships between social anxiety, smoking to cope, and cigarette craving. *Addict. Behav.* 37(8), 986–989. 10.1016/j.addbeh.2012.03.025 [PubMed: 22507303]
- Whelan BJ, & Savva GM (2013). Design and methodology of the Irish Longitudinal Study on Ageing. *J. Am. Geriatr. Soc.* 61, S265–S268. 10.1111/jgs.12199 [PubMed: 23662718]
- World Health Organization. (2017). *WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies* World Health Organization.
- Xu X, Bishop EE, Kennedy SM, Simpson SA, & Pechacek TF (2015). Annual healthcare spending attributable to cigarette smoking: an update. *Am. J. Prev. Med.* 48(3), 326–333. 10.1016/j.amepre.2014.10.012 [PubMed: 25498551]
- Zorlu N, Cropley VL, Zorlu PK, Delibas DH, Adibelli ZH, Baskin EP, ... & Pantelis C (2017). Effects of cigarette smoking on cortical thickness in major depressive disorder. *J. Psychiatric Res.* 84, 1–8. 10.1016/j.jpsychires.2016.09.009
- Zvolensky MJ, Baker KM, Leen- Feldner E, Bonn- Miller MO, Feldner MT, & Brown RA (2004). Anxiety sensitivity: association with intensity of retrospectively- rated smoking- related withdrawal symptoms and motivation to quit. *Cogn. Behav. Ther.* 33(3), 114–125. [PubMed: 15471381]
- Zvolensky MJ, Rosenfield D, Garey L, Kauffman BY, Langdon KJ, Powers MB, ... & Frierson GM (2018). Does exercise aid smoking cessation through reductions in anxiety sensitivity and dysphoria?. *Health Psychol.* 37(7), 647. 10.1037/hea0000588 [PubMed: 29708388]

**Table 1.**

Participant characteristics at baseline (n=6201)

Variable	
Smoking	
Never	2794 (45.1)
Former	2483 (41.0)
Current	924 (14.9)
GAD	566 (9.1)
Depression	686 (11.1)
Age	64.4 ±9.1
Sex	
Female	3404 (54.9)
Male	2797 (45.1)
Education	
Primary	1584 (25.5)
Secondary	2492 (40.2)
Tertiary	2125 (34.3)
Marital status	
Married	4403 (71.0)
Separated/divorced	451 (7.3)
Widowed	813 (13.1)
Never married	534 (8.6)
Physical activity	
Sufficient	3086 (49.8)
Insufficient	3115 (50.2)
Alcohol	
Non-problem drinker	4444 (71.7)
Problem drinker	700 (11.3)
Not reported	1057 (17.1)
Chronic conditions	
0	3062 (49.4)
1–2	2849 (45.9)
3+	290 (4.7)
Cardiovascular conditions	
0	5331 (86.0)
1–2	836 (13.5)
3+	34 (0.5)
Number of physical limitations	2.1±2.2

Numbers are N (%) or mean±standard deviation

Odds ratios (OR) and 95% confidence intervals (CI) derived from binominal logistic regression analyses as indicators of cross-sectional and prospective associations between smoking and generalised anxiety disorder (GAD) and major depression (MDD).

**Table 2.**

	Cross-sectional			Prospective		
	Cases/persons at risk	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Cases/persons at risk	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
	210/2794	REF	REF	65/2463	REF	REF
<b>GAD</b>						
Non-smoker	219/2483	1.261 (1.010 to 1.576)*	1.276 (1.008 to 1.616)*	57/2139	1.012 (0.665 to 1.542)	1.041 (0.672 to 1.614)
Former smoker	137/924	2.120 (1.655 to 2.716)**	1.729 (1.332 to 2.449)**	26/707	1.413 (0.869 to 2.296)	1.039 (0.624 to 1.730)
Current smoker						
	244/2794	REF	REF	135/2463	REF	REF
<b>MDD</b>						
Non-smoker	263/2483	1.198 (0.975 to 1.472)	1.191 (0.958 to 1.482)	140/2139	1.077 (0.815 to 1.424)	1.183 (0.889 to 1.573)
Former smoker	179/924	2.346 (1.862 to 2.955)**	1.967 (1.548 to 2.499)**	67/707	1.645 (1.175 to 2.303)**	1.399 (0.984 to 1.990)
Current smoker						

Adjusted model includes adjustment for age, sex, education, marital status, physical activity, chronic conditions, cardiovascular conditions, and number of physical limitations

\*  $p < 0.05$ ;

\*\*  $p < 0.001$